Product Name | NebuSelect™ Recombinant Human LOX1, His-tag |
---|---|
Catalog Number | NBL-240844 |
Alias/Synonyms | LOX1; Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1 |
Appearance | see COA |
Molecule Weight | Ser61-Gln273 |
CAS | N/A |
Solubility | Water Soluble |
Storage | Short term 4℃; Long term -20℃. |
Shelf Life | 2 years |
Additional info 1 | P78380-1 |
Additional info 2 |
Catalog Numbe | Size | Price | Inventory Level | |
NBL-240844-100ug | 100ug | Inquire | Inquire | |
NBL-240844-1mg | 1mg | Inquire | Inquire | |
NBL-240844-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human LOX1, His-tag
Catalog#:
NBL-240844
Description:
NebuSelect™ Recombinant Human LOX1, His-tag(Cat#NBL-240844) is expressed in HEK293 with His tag at the N-Terminus.It contains Ser61-Gln273.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 25.4 kDa. Due to glycosylation, the protein migrates to 30-36 kDa under reduced condition and 60-70 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Target Name:
LOX1; Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1
Target Information:
LOX-1 is a transmembrane glycoprotein that binds to and internalizes ox-LDL.LOX-1 gene deletion in mice and anti-LOX-1 therapy has been shown to decrease inflammation, oxidative stress and atherosclerosis. LOX-1 deletion also results in damage from ischemia, making LOX-1 a promising target of therapy for atherosclerosis and related disorders. In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis.
Amino Acid Sequence:
Ser61-Gln273
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.